These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38146642)

  • 1. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
    Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
    Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
    Dou X; Hua Y; Chen Z; Chao F; Li M
    Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma.
    Jiang J; Ye P; Sun N; Zhu W; Yang M; Yu M; Yu J; Zhang H; Gao Z; Zhang N; Guo S; Ji Y; Li S; Zhang C; Miao S; Chai M; Liu W; An Y; Hong J; Wei W; Zhang S; Qiu H
    Cancer Commun (Lond); 2024 Nov; 44(11):1350-1373. PubMed ID: 39340215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
    Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
    Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-MYH9 axis.
    Tang XY; Xiong YL; Zhao YB; Yang J; Shi AP; Zheng KF; Liu YJ; Shu C; Jiang T; Ma N; Zhao JB
    Front Immunol; 2022; 13():1014053. PubMed ID: 36268014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
    Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
    Front Immunol; 2022; 13():987639. PubMed ID: 36203609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
    Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
    Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
    Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
    J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
    Yoh KE; Lowe CJ; Mahajan S; Suttmann R; Nguy T; Reichelt M; Yang J; Melendez R; Li Y; Molinero L; Ruppel J; Xu W; Plaks V
    J Immunol Methods; 2021 Mar; 490():112936. PubMed ID: 33242493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.
    Liu Y; Lu M; Chen J; Li S; Deng Y; Yang S; Ou Q; Li J; Gao P; Luo Z; Yuan P; Tan J; Gao X
    Sleep Breath; 2022 Jun; 26(2):893-906. PubMed ID: 34254261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
    Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
    Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating
    Tang XY; Xiong YL; Shi AP; Sun Y; Han Q; Lv Y; Shi XG; Frattini M; Malhotra J; Zheng KF; Liu YJ; Jiang T; Ma N; Zhao JB
    Transl Lung Cancer Res; 2022 Mar; 11(3):404-419. PubMed ID: 35399566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.